The stock of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) reached all time low today, Oct, 28 and still has $9.66 target or 13.00% below today’s $11.10 share price. This indicates more downside for the $244.64 million company. This technical setup was reported by Barchart.com. If the $9.66 PT is reached, the company will be worth $31.80M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 132,035 shares traded hands or 23.56% up from the average. Paratek Pharmaceuticals Inc (NASDAQ:PRTK) has declined 23.47% since March 28, 2016 and is downtrending. It has underperformed by 28.18% the S&P500.
Analysts await Paratek Pharmaceuticals Inc (NASDAQ:PRTK) to report earnings on November, 10. They expect $-1.34 earnings per share, down 0.75% or $0.01 from last year’s $-1.33 per share. After $-1.69 actual earnings per share reported by Paratek Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -20.71% EPS growth.
Paratek Pharmaceuticals Inc (NASDAQ:PRTK) Ratings Coverage
Out of 6 analysts covering Paratek Pharmaceuticals (NASDAQ:PRTK), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Paratek Pharmaceuticals has been the topic of 10 analyst reports since July 23, 2015 according to StockzIntelligence Inc. On Wednesday, September 2 the stock rating was upgraded by Zacks to “Hold”. The stock has “Buy” rating given by H.C. Wainwright on Friday, June 17. The rating was upgraded by Zacks to “Sell” on Friday, August 14. The firm earned “Outperform” rating on Thursday, October 27 by Leerink Swann. The rating was upgraded by Zacks on Tuesday, September 22 to “Hold”. The stock of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) earned “Buy” rating by Gabelli on Thursday, July 23. The company was maintained on Friday, June 17 by Ladenburg Thalmann. As per Saturday, August 22, the company rating was downgraded by Zacks. Robert W. Baird initiated the shares of PRTK in a report on Friday, May 13 with “Outperform” rating. The stock of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) earned “Hold” rating by Zacks on Saturday, August 8.
According to Zacks Investment Research, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States.”
Insitutional Activity: The institutional sentiment increased to 5.42 in 2016 Q2. Its up 4.27, from 1.15 in 2016Q1. The ratio increased, as 5 funds sold all Paratek Pharmaceuticals Inc shares owned while 7 reduced positions. 28 funds bought stakes while 37 increased positions. They now own 29.25 million shares or 145.06% more from 11.93 million shares in 2016Q1.
Deutsche Savings Bank Ag last reported 95,180 shares in the company. Cubist Systematic Strategies Ltd Co last reported 0% of its portfolio in the stock. Goldman Sachs Grp Inc Incorporated last reported 0% of its portfolio in the stock. Peregrine Asset Advisers, a Oregon-based fund reported 11,800 shares. Bnp Paribas Arbitrage reported 563 shares or 0% of all its holdings. Rock Springs Capital Management L P last reported 0.43% of its portfolio in the stock. General Amer Invsts Inc has 0.69% invested in the company for 477,076 shares. Polar Capital Limited Liability Partnership holds 59,230 shares or 0.02% of its portfolio. Fny Managed Accounts Ltd Liability Company has 0% invested in the company for 1,000 shares. The United Kingdom-based Legal & General Group Inc Public Ltd Com has invested 0% in Paratek Pharmaceuticals Inc (NASDAQ:PRTK). Rhumbline Advisers holds 0% of its portfolio in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) for 13,792 shares. Moreover, Ardsley Advisory Prns has 0.02% invested in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) for 10,000 shares. Blackrock Investment Management Ltd owns 54,133 shares or 0% of their US portfolio. Moreover, Tiaa Cref Investment Ltd has 0% invested in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) for 48,462 shares. Brown Brothers Harriman And Company accumulated 367,902 shares or 0.03% of the stock.
More important recent Paratek Pharmaceuticals Inc (NASDAQ:PRTK) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on April 21, 2011, also Finance.Yahoo.com published article titled: “Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) to Ring The Nasdaq Stock Market …”, Quotes.Wsj.com published: “News Paratek Pharmaceuticals Inc.PRTK” on October 31, 2014. More interesting news about Paratek Pharmaceuticals Inc (NASDAQ:PRTK) was released by: Globenewswire.com and their article: “Paratek Pharmaceuticals Completes Merger With Transcept Pharmaceuticals” with publication date: October 30, 2014.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.